[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Westlake University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":238},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,61,94,116,143,164,193,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640355","westlake-frequent-sampling-cohort-2-100640355",false,"NCT07606885","Westlake Frequent-sampling Cohort 2","WeF2","Inclusion Criteria:\n\n* Participants reside in Hangzhou\n\nExclusion Criteria:\n\n* Refusing or unable to give informed consent\n* Participants with chronic gastrointestinal diseases and take daily relevant medications\n* Participants with metabolic diseases including diabetes, hypertension and cardiovascular diseases (CVD)\n* Participants with craniocerebral trauma, cancer, liver disease, kidney disease, or other critical illness, or history of operation or medication\n* Participants with bulimia nervosa, post-traumatic stress disorder (PTSD), chronic anxiety and depression or other critical neuronal disorder or history of relevant medication\n* Being or to be pregnant or lactating.\n* Participants with history of alcohol or drug addiction, or smoke above 15 cigarettes per day\n* Concurrently participating other clinical trials.",true,"ALL","18 Years","40 Years",{"count":21,"type":22},20,"ESTIMATED","OBSERVATIONAL","This observational follow-up study extends a previously completed 15-day intensive longitudinal study (WeF) of the gut microbiome in healthy adults. The objective of WeF2 is to characterize the long-term stability and dynamics of the gut and oral microbiota in the same cohort across multiple timescales, and to determine whether the day-to-day variability patterns observed at baseline persist over months and years. Participants who completed the WeF baseline protocol will be invited to attend periodic follow-up visits for low-frequency biospecimen collection and to repeat the original 15-day high-frequency sampling protocol at planned intervals, beginning approximately six months after the WeF baseline and continuing at extended intervals thereafter. By combining sparse routine sampling with recurring high-density sampling windows, the study aims to distinguish the stable core microbiome from transient and seasonal fluctuations, to track gradual community shifts under free-living conditions, and to further explore relationships among microbiome dynamics, dietary intake, and host glycemic regulation over an extended observation period.",[26,27],"Health Adults","Stability of Microbiome",[29],"Microbiome","RECRUITING","2026-05-19",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":22},"2026-05-08",{"date":38,"type":22},"2030-12-31",{"name":40,"class":41},"Westlake University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":42},"100628365","westlake-frequent-sampling-cohort-100628365","NCT07460687","Westlake Frequent-sampling Cohort","WeF",{"count":21,"type":22},"This intensive longitudinal study investigates the day-to-day stability and natural fluctuations of the gut microbiome in healthy adults over a 15-day period. While the human gut microbiome is a complex ecosystem, its baseline stability in the absence of disease or medical intervention remains insufficiently characterized due to low sampling frequency in prior research. By recruiting healthy volunteers for continuous daily sampling, this study aims to map temporal community structures and evaluate the stability of core microbiota. Additionally, the research utilizes Continuous Glucose Monitoring (CGM) to explore the potential relationships between microbiome dynamics, daily dietary intake, and host glycemic stability.",[26,27],[29],"2026-03-05",{"date":55,"type":34},"2026-03-10",{"date":57,"type":22},"2026-04-08",{"date":59,"type":22},"2027-12-31",{"name":40,"class":41},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":16,"sex":17,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100621655","westlake-aging-cohort-weac-100621655","NCT07373444","Westlake Aging Cohort (WeAC)","Westlake Aging Cohort","Inclusion Criteria:\n\n1. Age between 55 and 90 years (inclusive) at baseline.\n2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese.\n3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.\n4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB\u002FPDD patients.\n5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB\u002FPDD meets the core features of diagnosis.\n6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB\u002FPDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.\n\nExclusion Criteria:\n\n1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.\n2. Current use of psychoactive medications or any other drugs that may affect the study.\n3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.\n4. Participants with any other diseases that may affect the study.","55 Years","90 Years",{"count":71,"type":22},2800,"The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.",[74,75,76,77],"Aging","Cognition Improvement","Cognition Disorders","Cognition",[79,80,81,82,83],"aging","cognition","gut microbiota","multi-omics","brain","NOT_YET_RECRUITING","2026-01-19",{"date":87,"type":34},"2026-01-28",{"date":89,"type":22},"2026-01-01",{"date":91,"type":22},"2031-12-31",{"name":40,"class":41},2,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":16,"sex":17,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":42},"100581275","the-parkinsons-disease-case-control-study-100581275","NCT06848192","The Parkinson's Disease Case-Control Study","The Parkinson's Disease Case-Control Study: Gut Microbiome Study for Parkinson's Disease","Inclusion Criteria:\n\n(For PD patients)\n\n1. Men or women aged 50 to 75 years.\n2. Clinical diagnosis of Parkinson's disease (based on MDS Parkinson's disease diagnostic criteria)\n3. The patient must have at least two of the following symptoms: static tremor, bradykinesia, stiffness (which must include at least static tremor or bradykinesia); Or have asymmetrical resting tremors or asymmetrical bradykinesia.\n4. Able to provide informed consent.\n\n(For healthy volunteers)\n\n1. Age (±2 years) and sex-matched healthy control individuals for each Parkinson's disease patient.\n2. Able to provide informed consent.\n\nExclusion Criteria:\n\n(For PD patients)\n\n1. Atypical or secondary parkinsonism due to medications (e.g., metoclopramide, flunarizine, antipsychotics) or metabolic diseases (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).\n2. The presence of clinically diagnosed dementia as determined by the investigator.\n3. Previous MRI scans showed clinically significant neurological disorders (as judged by the investigator).\n4. Serious illness (e.g., heart failure or malignancy).\n5. Smoking more than 15 cigarettes a day and a history of alcohol or drug addiction\n6. Inflammatory gastrointestinal diseases.\n7. Chronic diseases that may affect the gut microorganism (e.g., diabetes, cirrhosis, or cardiovascular disease).\n8. Blood or autoimmune disease, or use of immunosuppressants in the past 3 months.\n9. Antibiotics have been used within 3 months prior to sample collection.\n10. Chronic constipation.\n\n(For healthy volunteers)\n\n1. Have a first-degree relative with Parkinson's disease (e.g. biological parent, sibling, or child).\n2. Current or past clinically significant neurological disorders (as judged by the investigator).\n3. Previous MRI scans showed clinically significant neurological disorders (as judged by the investigator).\n4. Use of the following drugs in the 6 months prior to the screening visit: dopamine blockers (antipsychotics), metoclopramide, and riserpine.\n5. Inflammatory gastrointestinal diseases.\n6. Smoking more than 15 cigarettes a day and a history of alcohol or drug addiction\n7. Chronic diseases that may affect the gut microorganism (e.g., diabetes, cirrhosis, or cardiovascular disease).\n8. Blood or autoimmune disease, or use of immunosuppressants in the past 3 months.\n9. Antibiotics have been used within 3 months prior to sample collection.\n10. Chronic constipation.\n11. Participating in other clinical trials","50 Years","75 Years",{"count":104,"type":22},40,"The Parkinson's Disease Case-Control Study is a study of healthy volunteers and patients with Parkinson's disease aged 50-75 years living in Hangzhou, China. This study aims to systematically investigate the differences in intestinal fungi between patients and healthy volunteers, find the key strains, and explore the molecular mechanism of Parkinson's disease with multi-omics data. Another aim of this study is to explore the association between intestinal fungi and brain structure and function from the perspective of the gut-brain axis by combining brain image data.",[107],"Parkinson Disease","2025-06-10",{"date":110,"type":34},"2025-06-13",{"date":112,"type":34},"2025-03-05",{"date":114,"type":22},"2025-12",{"name":40,"class":41},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":122,"maxAge":102,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":93},"100507318","the-precision-t2d-study-precision-nutrition-study-for-type-2-diabetes-100507318","NCT05885828","The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes;\n* Living in Hangzhou for at least five years;\n* Have the willingness or ability to complete the intervention and sample collection\n\nExclusion Criteria:\n\n* Mental and physical disability;\n* Already is a vegetarian;\n* Cancer and serious complications from type 2 diabetes, such as renal failure;\n* Using insulin for more than 5 years;\n* Unstable medical\u002Fmedication status;\n* Current alcohol or drug abuse;\n* Taking antibiotics in the last three months","35 Years",{"count":124,"type":22},200,"INTERVENTIONAL",[127],"NA","Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.\n\nIn this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.",[130],"Type 2 Diabetes",[132,133,134,135,136],"N-of-1","plant-based diet","precision nutrition","continuous glucose monitoring","type 2 diabetes",{"date":110,"type":34},{"date":139,"type":34},"2023-07-17",{"date":141,"type":22},"2033-12-01",{"name":40,"class":41},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":150,"targetDuration":152,"studyType":23,"phases":4,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":42},"100458948","westlake-longevity-cohort-100458948","NCT05256251","Westlake Longevity Cohort","We-Longevity","Inclusion Criteria:\n\n* Participants live in Lishui, China.\n* Participants intend to remain in Lishui for ≥3 years.\n\nExclusion Criteria:\n\n* Participants with infectious diseases.",{"count":151,"type":22},1500,"3 Years","The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians and senior citizens living in Lishui, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. The second aim is to culture the gut microbiota of these elderly people through culturomics. The third aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional\u002Flifestyle recommendation for the public.",[74],[156,74],"Gut microbiome",{"date":158,"type":34},"2025-06-15",{"date":160,"type":34},"2021-11-15",{"date":162,"type":22},"2031-11-14",{"name":40,"class":41},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":171,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":125,"phases":174,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":42},"100500276","wenzhou-gestational-diabetes-cohort-100500276","NCT05794152","Wenzhou Gestational Diabetes Cohort","WGDC","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Women with GDM mainly at 24-28 weeks of gestation\n* Women intended to deliver at Wenzhou People's Hospital\n* Women intended to remain in Wenzhou with their child for ≥4 years\n\nExclusion Criteria:\n\n* Women with cancer and other serious medical disorders","FEMALE",{"count":173,"type":22},300,[127],"The Wenzhou Gestational Diabetes Cohort (WGDC) is a prospective cohort study among women with gestational diabetes mellitus (GDM) during pregnancy and their offspring living in Wenzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with GDM over 2 weeks, and to facilitate the development of personalized nutritional\u002Flifestyle recommendation among these patients. Another aim of the WGDC is to investigate the association of dietary and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the patients with long-term metabolic health of the women and their offspring.",[177,178,179,180],"Gestational Diabetes Mellitus","Intrauterine Hyperglycemia","Birth Outcome, Adverse","Nutrition, Healthy",[182,183,184],"Precision Nutrition","Host and Microbiome","Birth Outcomes","2025-03-30",{"date":187,"type":34},"2025-04-03",{"date":189,"type":34},"2023-03-21",{"date":191,"type":22},"2033-03-21",{"name":40,"class":41},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":42},"100576705","study-of-clostridioides-difficile-in-infants-100576705","NCT06788769","Study of Clostridioides Difficile in Infants","Retrospective Analysis of Risk Factors and Microbiome Alterations in Infant Clostridioides Difficile Infection","Inclusion Criteria:\n\n1. Age Range: Infants aged 0 to 2 years (inclusive) at the time of sample collection or medical record documentation.\n2. Data Availability: Complete medical records or available stool samples within the study's retrospective time frame.\n3. Group-Specific Criteria:\n\n   CDI Patients: Documented diarrhea or related gastrointestinal symptoms, with laboratory-confirmed C. difficile by PCR or culture.\n\n   Asymptomatic Carriers: Positive C. difficile test (PCR or culture) in the absence of diarrhea or other clinical CDI symptoms.\n\n   Healthy Controls: Negative C. difficile test and no gastrointestinal symptoms indicative of CDI.\n4. Consent\u002FAuthorization:Retrospective data (e.g., existing medical records or stored biosamples) may be included under a waiver of consent if approved by the institutional review board (IRB). However, any new information obtained directly from participants or their guardians (e.g., via questionnaires) requires explicit informed consent.\n\nExclusion Criteria:\n\n1. Incomplete Data: Infants whose medical records lack sufficient information to confirm their CDI status or those without adequate stool sample results.\n2. Ambiguous Diagnosis: Patients presenting with other infectious diseases or conditions that could not rule out alternative diagnoses for diarrhea (e.g., confirmed concurrent viral or parasitic infections) without conclusive C. difficile testing.\n3. Severe Comorbidities: Infants with life-threatening congenital conditions (e.g., severe immunodeficiency syndromes) if these conditions significantly alter the gut microbiota or confound CDI diagnosis.","1 Day","2 Years",{"count":173,"type":22},"Clostridioides difficile infection (CDI) poses an increasing threat to infant and young child health, with detection rates rising annually. This retrospective study aims to explore the epidemiological characteristics, clinical manifestations, and potential biomarkers of CDI in children aged 0-2 years by examining three cohorts: (1) infants diagnosed with CDI, (2) asymptomatic carriers of C. difficile, and (3) healthy controls. Fecal samples from each group will undergo metagenomic sequencing and metabolomic profiling, coupled with questionnaire-based surveys for risk factor assessment. The findings are anticipated to identify key high-risk factors, elucidate the pathogenic mechanisms underlying infant CDI, and support the development of early diagnostic tools and preventive strategies.",[205],"Clostridioides Difficile Infection",[207,208],"Clostridioides Difficile","Infants","2025-01-16",{"date":211,"type":34},"2025-01-23",{"date":213,"type":34},"2024-07-01",{"date":215,"type":22},"2026-12-30",{"name":40,"class":41},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":125,"phases":225,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":42},"100543391","phase-1-a-study-of-the-efficacy-of-troxerutin-in-preventing-thrombotic-events-in-covid-19-patients-100543391","NCT06355258","A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients","Inclusion Criteria:\n\nAs long as the patient meets all of the following conditions, adult patients aged 18 and above are eligible for admission:\n\n► COVID-19 patients, defined as: positive RT-PCR (upper respiratory tract or lower respiratory tract) for SARS-CoV-2.\n\nMild COVID-19 patients are defined as:\n\nSymptomatic patients meeting the case definition for COVID-19 without evidence of hypoxia or pneumonia. Common symptoms include fever, cough, fatigue, anorexia, dyspnea, and myalgia. Other nonspecific symptoms include sore throat, nasal congestion, headache, diarrhea, nausea\u002Fvomiting, and loss of smell\u002Ftaste.\n\nSevere COVID-19 patients are defined as:\n\nAdolescents or adults with clinical signs of pneumonia (i.e., fever, cough, dyspnea, tachypnea) plus one of the following:\n\n1. Respiratory rate ≥30 breaths\u002Fmin\n2. Severe respiratory distress\n3. Oxygen saturation (SpO₂) ≤90% in room air\n4. Progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (\\>50%) within 24 to 48 hours.\n\n   * Written informed consent provided according to Chinese law (by the patient, legal guardian, or deferred consent in emergencies).\n\nExclusion Criteria:\n\nPatients with any of the following conditions will be excluded from the study:\n\n* Pregnant or lactating women.\n* Postpartum (within 6 weeks).\n* Extreme weight (100 kilograms).\n* Clinical need for heparin therapy.\n* Bleeding related to coagulation disorders, acute clinically significant bleeding, active gastrointestinal ulcers, or any organic lesions with high bleeding risk.\n* Platelet count \\\u003C50 x 10\\^9\u002FL.\n* Surgery within the last 15 days, or within 24 hours after spinal or epidural anesthesia.\n* History of intracranial hemorrhage, large ischemic stroke, known intracranial malformation or tumor, acute infective endocarditis.\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin).\n* Iodine allergy.\n* Long-term use of oxygen supplementation.\n* Moribund patients or those expected to die during the current hospitalization due to underlying disease.\n* Patients deprived of freedom and those undergoing institutional psychiatric care.\n* Ward of the state or under guardianship.\n* Participation in other anticoagulant intervention studies.",{"count":224,"type":22},80,[226],"PHASE1","The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:\n\n* Does troxerutin lower the number of thrombotic events in participants?\n* What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients.\n\nParticipants will:\n\n* Take troxerutin or a placebo every day for 7 days.\n* Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests\n* Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia",[229],"COVID 19 Associated Coagulopathy","2024-11-10",{"date":232,"type":34},"2024-11-12",{"date":234,"type":34},"2023-12-15",{"date":236,"type":22},"2025-03",{"name":40,"class":41},""]